secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-08-13T20:07:54+00:00
Accession:  0001619856-26-000053
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q2 2026 net loss $24.3M; vispa-cel and CB-011 show strong efficacy data
-------------------------------------------------------------------------------

- Q2 2026 net loss $24.3M ($0.24/share) vs $54.1M ($0.58) in Q2 2025, which included $21.3M impairment.
- Revenue $1.5M vs $2.7M; R&D $18.9M vs $27.7M; G&A $7.9M vs $10.4M.
- Cash $113.8M at June 30, 2026, expected to fund operations to end of 2027.
- ANTLER data: 82% ORR, 67% CR, 17.1-month median PFS in 2L LBCL (N=27) for vispa-cel.
- CB-011 CaMMouflage: 92% ORR, 83% ≥CR, 91% MRD negativity; initial dose expansion data expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/0001619856-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001619856-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer